Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Paul J Declerck"'
Autor:
Machteld Sillen, Paul J. Declerck
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 7 (2020)
Plasminogen activator inhibitor-1 (PAI-1), a member of the serine protease inhibitor (serpin) superfamily with antiprotease activity, is the main physiological inhibitor of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators (PAs). Apar
Externí odkaz:
https://doaj.org/article/686f58e62cc149758ae1a91ce331d8cd
Autor:
Tobias Kromann-Hansen, Eva Louise Lange, Hans Peter Sørensen, Gholamreza Hassanzadeh-Ghassabeh, Mingdong Huang, Jan K. Jensen, Serge Muyldermans, Paul J. Declerck, Elizabeth A. Komives, Peter A. Andreasen
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Abstract Although trypsin-like serine proteases have flexible surface-exposed loops and are known to adopt higher and lower activity conformations, structural determinants for the different conformations have remained largely obscure. The trypsin-lik
Externí odkaz:
https://doaj.org/article/409897e4334a4c2c81d516f9a73f9d64
Autor:
Kevin Hollevoet, Paul J. Declerck
Publikováno v:
Journal of Translational Medicine, Vol 15, Iss 1, Pp 1-19 (2017)
Abstract Recombinant monoclonal antibodies (mAbs) are one of today’s most successful therapeutic classes in inflammatory diseases and oncology. A wider accessibility and implementation, however, is hampered by the high product cost and prolonged ne
Externí odkaz:
https://doaj.org/article/939df91fba7346f2a147a6628254eb82
Autor:
Machteld Sillen, Paul J. Declerck
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 7, p 3670 (2021)
Thrombin activatable fibrinolysis inhibitor (TAFI), a proenzyme, is converted to a potent attenuator of the fibrinolytic system upon activation by thrombin, plasmin, or the thrombin/thrombomodulin complex. Since TAFI forms a molecular link between co
Externí odkaz:
https://doaj.org/article/44cf82f59f9a4ac6bb98db6629a6a01e
Autor:
Machteld Sillen, Paul J. Declerck
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 5, p 2721 (2021)
Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of plasminogen activators (PAs) and is therefore an important inhibitor of the plasminogen/plasmin system. Being the fast-acting inhibitor of tissue-type PA (tPA), PAI-1 pr
Externí odkaz:
https://doaj.org/article/bbd110fb07d8473e98a582f10a8e9682
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 3, p 1482 (2021)
Plasminogen activator inhibitor-1 (PAI-1), a key regulator of the fibrinolytic system, is the main physiological inhibitor of plasminogen activators. By interacting with matrix components, including vitronectin (Vn), PAI-1 plays a regulatory role in
Externí odkaz:
https://doaj.org/article/ff59cadfee3644879d36b83f98b8fa2c
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 16, p 5859 (2020)
Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators (PAs). Apart from being critically involved in fibrinolysis and wound healing, emerging evidence indica
Externí odkaz:
https://doaj.org/article/743b757b599a421d919696c38680ad08
Autor:
Shiraazkhan Abdul, Miet Peeters, Els Brouwers, Joyce J M C Malfliet, Frank W G Leebeek, Paul J Declerck, Dingeman C Rijken, Shirley Uitte de Willige
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0196911 (2018)
Around 70% of circulating alpha-2-antiplasmin (α2AP), the main natural plasmin inhibitor, is N-terminally cleaved between residues Pro12 and Asn13 by antiplasmin-cleaving enzyme. This converts native Met-α2AP into the more potent fibrinolysis inhib
Externí odkaz:
https://doaj.org/article/e2a6b9d1253348ceb014e9f164bf1048
Autor:
Sebastian Seidl, Nis Valentin Nielsen, Michael Escheid, Bengt Erik Haug, Maria Stensland, Bernd Thiede, Paul J. Declerck, Geir Åge Løset, Sandip M. Kanse
Increased Factor VII activating protease (FSAP) activity has a protective effect in diverse disease conditions as inferred from studies in FSAP−/− mice and humans deficient in FSAP activity due to a single nucleotide polymorphism. The activation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1bab935607a25f3e39e2a20180ce336
https://doi.org/10.1101/2022.01.09.475526
https://doi.org/10.1101/2022.01.09.475526
Autor:
Sebastian Berge-Seidl, Nis Valentin Nielsen, Armando A. Rodriguez Alfonso, Michael Etscheid, Sai Priya Sarma Kandanur, Bengt Erik Haug, Maria Stensland, Bernd Thiede, Merve Karacan, Nico Preising, Sebastian Wiese, Ludger Ständker, Paul J. Declerck, Geir Åge Løset, Sandip M. Kanse
Publikováno v:
ACS Chemical Biology
2631–2642
2631–2642
Factor VII Activating protease (FSAP) has a protective effect in diverse disease conditions as inferred from studies in FSAP-/- mice and humans deficient in FSAP activity due to single-nucleotide polymorphism. The zymogen form of FSAP in plasma is ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::575d9f37fe86a28755688db593e0dc61
https://hdl.handle.net/11250/3029761
https://hdl.handle.net/11250/3029761